Ronacaleret

Drug Profile

Ronacaleret

Alternative Names: 751689; Ronacaleret Hydrochloride; SB-751,689; SB-751689-A

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator NPS Pharmaceuticals
  • Developer GlaxoSmithKline
  • Class Osteoporosis therapies; Propionic acids; Small molecules
  • Mechanism of Action Calcium-sensing receptor antagonists; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Fracture; Postmenopausal osteoporosis; Stem cell mobilisation

Most Recent Events

  • 01 Mar 2016 Discontinued - Phase-I for Postmenopausal osteoporosis (In volunteers) in USA (PO) (NCT00651534)
  • 21 Jul 2015 Discontinued - Phase-II for Stem cell mobilisation in USA (PO)
  • 21 Feb 2015 NPS Pharmaceuticals has been acquired by Shire
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top